XOMA Corp
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About XOMAO
XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. Its royalty portfolio includes AFM13, AFM24, AB002 (proCase/E-WE thrombin), AB023 (xisomab, 3G3), AB054, AZD2936, AV-299 (ficlatuzumab), BAY1213790 (osocimab), CMP-001 (vidutolimod), Lysosomal Storage Disorders Enzymes, COM902, DAY101 (tovorafenib), vosaroxin, INCAGN1876, INCAGN1949, INCAGN02390, INCAGN2385, JNJ-63723283 (cetrelimab), MK-4830, MT-0169, CFZ533 (iscalimab), VPM087 (gevokizumab), NIS793, NIR178, G03-52-01, ebopiprant, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ358, RZ402, faricimab (faricimab-svoa), TAK-079 (mezagitamab), Aldoxorubicin, and Arimoclomol. The Company's subsidiaries include XOMA Technology Ltd., XOMA (US) LLC, and XOMA UK Limited.
-
-
8.20%
0
$25.55
$25.46
$0.00
$25.76
$23.32
Ready to start your investing journey with Stake?
Open an accountXOMAO FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in XOMAO
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in XOMAO
on Stake
Buy XOMAO from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of XOMAO from only US$10 with fractional shares
